DP-QB-MYA-002
Phase 1Biologic
DP-QB-MYA-002 is one of 39 biologic programs targeting Abscess. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
38
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
64 competitors in Abscess
#DrugCompanyPhaseTrials
1Valtrex
GGlaxo Dba Glaxosmithkline
Approved
Duragesic
CCephalon
Approved
Flagyl
DDePuy Orthopaedics
Approved
Activase
RochePhase 3
Primaxin
PfizerPhase 3
Mycobutin
PfizerPhase 3
Biaxin
AbbViePhase 3
Sirturo
WWim Janssens
Phase 3
MS Contin
HHikma Pharmaceuticals LLC
Phase 3
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DP-QB-MYA-002. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- AAlberta Health services